We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOUR:NASDAQTuniu Corporation Analysis

Data as of 2026-09-01 - not real-time

$4.83

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $4.83, Tuniu Corporation shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has lost 5.5%. With RSI at 44.1 the momentum picture is neutral, alongside a bearish MACD signal. The recent range runs from support at $4.71 up to resistance at $5.30.
Multiples put this in undervalued territory at a P/E of 11.0. Sell-side targets cluster 69.8% above the current quote. Revenue is growing at 3.0% on a 3.8% profit margin. The 24.04% dividend yield looks stretched against payout coverage.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 32.0%, a beta of 0.83 and a maximum drawdown of 52.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.

Top Market Events

Tuniu Corporation NASDAQ:TOUR reported higher second-quarter revenue on Tuesday and extended its run of adjusted...NANJING, China, Aug. 25, 2026 /PRNewswire/ -- Tuniu Corporation NASDAQ: TOUR "Tuniu" or the "Company" , a leading...Tuniu Corporation NASDAQ:TOUR "Tuniu" or the "Company" , a leading online leisure travel company in China, today...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 6.26
  • MACD momentum is negative
  • 30-day price change of -5.5%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Dividend yield of 24.04% looks stretched against payout coverage
  • Trading below the 200-day average of 6.26
  • Analyst targets imply +69.8% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Dividend yield of 24.04% looks stretched against payout coverage
  • Analyst targets imply +69.8% versus the current price
  • P/E ratio of 11.0

Key Metrics & Analysis

Financial Health

Revenue Growth3.00%
Profit Margin3.80%
P/E Ratio11.0
ROE2.36%
ROA0.83%
Debt/Equity0.54
P/B Ratio0.3

Technical Analysis

TrendNeutral
RSI44.1
Support$4.71
Resistance$5.30
MA 20$4.97
MA 50$4.96
MA 200$6.26
MACDBearish
VolumeDecreasing
Fear & Greed Index94.45

Valuation

Target Price$8.20
Upside/Downside69.82%
GradeUndervalued
TypeValue
Dividend Yield24.04%

Risk Assessment

Beta0.83
Volatility31.98%
Sector RiskHigh
Reg. RiskLow
Geo RiskHigh
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.